UPMC Hillman Cancer Center will soon host a huge clinical trial to treat a rare and aggressive form of cancer that affects more than 20,000 people each year in the U.S. alone.
UPMC announced Monday that John C. Byrd had been named Hillman Cancer Center director and he is the principal investigator and chief medical officer of a long-running clinical trial for the treatment of acute myeloid leukemia. AML comprises fewer than 1% of new cancer cases, but fewer than one-third of patients with the disease survive more than five years.
The Beat AML Master Clinical Trial targets mostly newly diagnosed and elderly patients, using rapid genomic analysis of leukemia cells to identify specific subtypes of the disease. Once matched, patients are quickly treated with targeted therapies rather than the standard one-size-fits-all chemotherapy.
Dr. Byrd starts at Hillman in November.
The Leukemia and Lymphoma Society is sponsoring the clinical trials, which are being conducted at 16 cancer centers around the country. The precision medicine study was launched in 2016.
A number of new medications will be used in the trials, Dr. Byrd said.
“We’re changing the paradigm of AML,” he said. “We’ll be bringing the trial to Pittsburgh.”
Dr. Byrd replaces Robert L. Ferris, who left Hillman last year.
Dr. Byrd comes to Hillman from the University of Cincinnati, where he has chaired the Department of Internal Medicine since 2021. Previously, he was at the Ohio State University Comprehensive Cancer Center — James Cancer Hospital and Solove Research Institute, where he served as senior adviser for cancer experimental therapeutics and distinguished university professor.
“We are thrilled to welcome Dr. Byrd and his extensive experience in conducting and supporting internationally influential cancer research, developing and overseeing premier programmatic efforts and elevating holistic patient care,” Anantha Shekhar, senior vice chancellor for the health sciences at the University of Pittsburgh, said in a prepared statement.
Dr. Byrd has over 600 publications in the area of leukemia and experimental therapeutics research. He has been part of the successful development of multiple therapeutics in acute myeloid leukemia and chronic lymphocytic leukemia.
Dr. Byrd received his medical degree from the University of Arkansas for Medical Sciences, then continued his education in internal medicine and hematology and oncology at Walter Reed Army Medical Center and Johns Hopkins University before moving to Columbus to join the Ohio State faculty in 2001.
At Ohio State, Dr. Byrd was the D. Warren Brown Chair of Leukemia Research and professor of medicine, medical chemistry and veterinary biosciences. He is a board-certified hematologist whose clinical practice focuses on caring for patients with chronic lymphocytic leukemia, the most common leukemia, and acute myeloid leukemia, which is relatively rare.
Dr. Ferris left UPMC in October to become executive director of the UNC Lineberger Comprehensive Cancer Center and chief of oncology clinical services at the University of North Carolina, Chapel Hill. He was succeeded at Hillman by two interim directors.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.